With respect to the clinical impact of GATA3 immunopositivity in cHL, a previous study reported that the GATA3+ cHL group was significantly associated with an increase in the number of lymph node sites compared to GATA3- cHL (p = 0.007) (taking 10% as the threshold of positivity, which was the lowest value) [14]. This evidence concerns the gene GATA3 and classic Hodgkin lymphoma.